Received May 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (INFANRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 9KB9G | — |
Unapproved age; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 11-year-old female patient who received DTPa (Infanrix) (batch number 9KB9G, expiry date 07-JUL-2026) for prophylaxis. Concomitant products included Diphtheria vaccine toxoid, Pertussis vaccine acellular 3-component, Tetanus vaccine toxoid (Boostrix). On 14-MAY-2025, the patient received Infanrix. On 14-MAY-2025, an unknown time after receiving Infanrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Unapproved age). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 14-MAY-2025 Office Manager reported that they had a patient in office today. So, they gave her a dtap and a tdap vaccine. So, they were just wondering if there were any contraindications that they need to be concerned about? Consented to follow up. The second line agent provided the information that with this Infanrix shot at the age of 11 years which led to inappropriate age at vaccine administration, patient had 5 DTAP vaccines.
BOOSTRIX